Invest now
Divi's Laboratories Key Metrics
BSE: 532488 | NSE: DIVISLAB | ISIN: INE361B01024 | Sector: Biotechnology & Drugs8,248.50 -43.05 (-0.52%)Updated : 07 Aug 2026
Research on
Ratios
| Return on average equity - 5 year average | 16.87 |
| Net Income/employee - trailing 12 month | 15,15,544.00 |
| Revenue/employee - most recent fiscal year | 56,17,022.00 |
| Return on investment - most recent fiscal year | 15.35 |
| Return on average assets - most recent fiscal year | 13.89 |
| Receivables turnover - most recent fiscal year | 3.62 |
| Return on investment - trailing 12 month | 0.00 |
| Return on average assets - trailing 12 month | 0.00 |
| Inventory turnover - most recent fiscal year | 1.31 |
| Inventory turnover - trailing 12 month | 0.00 |
| Revenue/employee - trailing 12 month | 58,18,653.00 |
| Return on average assets - 5 year average | 14.74 |
| Net Income/employee - most recent fiscal year | 13,65,958.00 |
| Return on average equity - trailing 12 month | 0.00 |
| Receivables turnover - trailing 12 month | 0.00 |
| Asset turnover - most recent fiscal year | 0.57 |
| Asset turnover - trailing 12 month | 0.00 |
| Return on average equity - most recent fiscal year | 16.19 |
| Return on investment - 5 year average | 16.15 |
Divi's Laboratories Quick Links
Divi's Laboratories Dividend Divi's Laboratories Bonus Divi's Laboratories News Divi's Laboratories AGM Divi's Laboratories Rights Divi's Laboratories Splits Divi's Laboratories Board Meetings Divi's Laboratories Shareholdings Divi's Laboratories Profit Loss Divi's Laboratories Balance Sheet Divi's Laboratories Cashflow Divi's Laboratories Q1 Results Divi's Laboratories Q2 Results Divi's Laboratories Q3 Results Divi's Laboratories Q4 Results
Equity Quick Links
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks
2,427.00+57.00(2.41%)
1,653.95+18.95(1.16%)
3,443.60+28.60(0.84%)
1,093.40-56.50 (-4.91%)
2,007.00-82.25 (-3.94%)
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.